BioNxt Solutions Inc. (CSE: BNXT)

Canada flag Canada · Delayed Price · Currency is CAD
0.420
+0.010 (2.44%)
Jan 21, 2025, 4:00 PM EST
-40.85%
Market Cap 46.49M
Revenue (ttm) 42.01K
Net Income (ttm) -6.48M
Shares Out 113.40M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 268,105
Average Volume 112,473
Open 0.410
Previous Close 0.410
Day's Range 0.405 - 0.430
52-Week Range 0.170 - 0.700
Beta 0.53
RSI 63.12
Earnings Date Apr 22, 2025

About BioNxt Solutions

BioNxt Solutions Inc. engages in R&D and manufacturing of thin-film (sublingual) and skin patch (transdermal) drug delivery for neurological and autoimmune diseases, enhancing patient compliance and bioavailability. It offers diagnostic screening tests, and new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was f... [Read more]

Sector Healthcare
Founded 2017
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol BNXT
Full Company Profile

Financial Performance

In 2023, BioNxt Solutions's revenue was 372,247, an increase of 25.15% compared to the previous year's 297,442. Losses were -7.72 million, -37.60% less than in 2022.

Financial Statements

News

There is no news available yet.